Skip to main content
. 2018 Mar 19;10(3):453–462. doi: 10.1080/19420862.2018.1433974

Figure 5.

Figure 5.

In vivo protection against RSV infection by intranasally administered RSV-specific IgA and IgG. RSV load was determined in bronchoalveolar fluid from wild-type (WT; closed circles) and human FcαRI transgenic (Tg; open squares) BALB/c mice prophylactically treated with recombinant IgA and IgG variants of (A) palivizumab and (B) motavizumab. Graphs show the percentage of RSV infection; the mean RSV load of the PBS-treated group was set to 100% infection. N=5 mice per group. Data represent the mean ± SEM. Kruskal-Wallis test, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.